US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% STX $945.57 ▲+0.00% SNDK $1,787.69 ▲+0.00% WDC $462.56 ▲+0.00% NKE $35.15 ▲+0.00% AMD $615.73 ▲+0.00% MSTR $160.50 ▲+0.00%
FinancialContent

Bone Biologics Corp - Common Stock (NQ:BBLG)

0.4750 +0.0050 (+1.06%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bone Biologics Corp - Common Stock

< Previous 1 2 Next >
News headline image
Bone Biologics Expands Trial Sites
Addition of three sites strengthens expectation to complete enrollment by year-end 2026 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
Milestone strengthens manufacturing flexibility and supports pivotal study readiness 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Milestone advances manufacturing readiness and supports long-term commercialization strategy 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Closing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Valuation, Nasdaq Compliance Etc. – More Stocks Inside
Via AB Newswire
Topics Regulatory Compliance
News headline image
Bone Biologics Announces Pricing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Files Patent Application for Bone Regeneration Technology
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces 1-for-6 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
From Bone Biologics
Via Business Wire
News headline image
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Bone Biologics Corporation
Via Business Wire
News headline image
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
From Bone Biologics Corporation
Via Business Wire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Bone Biologics Announces Closing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Pricing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Reports Progress With NB1 Clinical Program
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces 1-for-8 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
< Previous 1 2 Next >